IBI 3005
Alternative Names: IBI-3005Latest Information Update: 03 Jun 2024
At a glance
- Originator Innovent Biologics
- Class Antineoplastics; Bispecific antibodies; Camptothecins; Drug conjugates; Immunotherapies
- Mechanism of Action DNA topoisomerase I inhibitors; Hypoxia-inducible factor 1 alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 22 May 2024 Preclinical trials in Solid tumours in China (Parenteral)
- 22 May 2024 Innovent Biologics plans a phase I trial in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease) (NCT06418061)